Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05828849 · ClinicalTrials.gov registry record · NA
Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk
A NA study of Alcohol Use Disorder and Cardiovascular Disease, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT05828849: Active NA study of Alcohol Use Disorder and Cardiovascular Disease, sponsored by NYU Langone Health.
NCT05828849 is a NA study of Alcohol Use Disorder and Cardiovascular Disease that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 87 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05828849, a NA study of Alcohol Use Disorder and Cardiovascular Disease, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to investigate if a personalized intervention including parts such as navigation (focus on patient outreach efforts, missed and completed encounters), personalization (individual health benefits) and compensation (value health-related costs borne by patients) will help people reduce their chances of dying from preventable causes, including heart attacks, strokes, drinking alcohol, substance abuse, HIV, and other conditions.
Primary Outcome
10-item self-assessment of alcohol use disorders. Items are rated on a scale from 0 to 4. The total score is the sum of responses and ranges from 0-40; higher scores indicate it is more likely the patient's drinking is affecting their health and safety.
Conditions Studied
Interventions
- BEHAVIORAL Navigation, compensation, and personalization
Study Locations (1)
New York
- NYC H+H/Bellevue - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2026-07 |
| Phase | NA |
What the registry record for NCT05828849 still lists
NCT05828849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (73% lower).
The record links to 4 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Navigation, compensation, and personalization is the first listed.
NCT05828849 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05828849 about?
NCT05828849 is a clinical study titled "Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk". The purpose of this research study is to investigate if a personalized intervention including parts such as navigation (focus on patient outreach efforts, missed and completed encounters), personalization (individual health benefits) and compensation (value health-related costs borne by patients) wi...
What is the current status of trial NCT05828849?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 87 participants. The study started on 2024-06-25. Estimated completion is 2026-07.
What conditions does trial NCT05828849 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Cardiovascular Disease, Substance Use Disorders, HIV Risk.
What interventions are being tested in trial NCT05828849?
The interventions under investigation include: Navigation, compensation, and personalization (BEHAVIORAL).
Who is sponsoring clinical trial NCT05828849?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05828849 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05828849's enrollment target sits among peer trials
87 96th of 184 higher than 89 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI